Literature DB >> 11375054

Elevated plasma stromal cell-derived factor 1 protein level in the progression of HIV type 1 infection/AIDS.

M Ikegawa1, J Yuan, K Matsumoto, S Herrmann, A Iwamoto, T Nakamura, S Matsushita, T Kimura, T Honjo, K Tashiro.   

Abstract

Stromal cell-derived factor 1 (SDF-1) is a unique chemokine involved in multiple organogenesis as well as in the regulation of HIV infection. Here we determined the plasma SDF-1 concentrations of 193 HIV-1-infected individuals and 154 normal Japanese volunteers by developing a highly sensitive measurement system based on time-resolved fluoroimmunoassay (SDF-1 TR-FIA). This system is also valid for the mouse model to quantitate circulating SDF-1 concentration in vivo and thereby its correlation with CXCR4 expression level on CD4(+) T cells. Interestingly, plasma SDF-1 concentrations in HIV-1-infected individuals were three times higher than those in a normal control group and plasma SDF-1 protein levels showed an inverse correlation with CD4(+) T cell count and a positive correlation with plasma HIV-1 RNA load. Notably, individuals with later stage HIV-1 infection, who maintained fewer than 200 CD4(+) T cells per cubic milliliter and more than 10,000 copies of HIV-1 RNA per milliliter, showed the highest plasma SDF-1 level among individuals at any stage of HIV-1 infection. These results suggest that endogenous SDF-1 is upregulated by HIV-1 infection, particularly in late-stage HIV-1 infection/AIDS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375054     DOI: 10.1089/088922201300119680

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  CCR2, CCR5, and CXCL12 variation and HIV/AIDS in Papua New Guinea.

Authors:  Noemi B Hall; Shannon E Bruse; Bangan John; Rajeev K Mehlotra; Melinda J Blood Zikursh; Catherine M Stein; Peter M Siba; Peter A Zimmerman
Journal:  Infect Genet Evol       Date:  2015-09-28       Impact factor: 3.342

2.  Risk for HIV-1 infection associated with a common CXCL12 (SDF1) polymorphism and CXCR4 variation in an African population.

Authors:  Desiree C Petersen; Richard H Glashoff; Sadeep Shrestha; Julie Bergeron; Annette Laten; Bert Gold; Estrelita Janse van Rensburg; Michael Dean; Vanessa M Hayes
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-15       Impact factor: 3.731

Review 3.  Lanthanide complex-based fluorescence label for time-resolved fluorescence bioassay.

Authors:  Jingli Yuan; Guilan Wang
Journal:  J Fluoresc       Date:  2005-07       Impact factor: 2.217

4.  Endogenous Peptide Inhibitors of HIV Entry.

Authors:  Mirja Harms; Manuel Hayn; Fabian Zech; Frank Kirchhoff; Jan Münch
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Stromal cell-derived factor 1 polymorphism in patients infected with HIV and implications for AIDS progression in Tunisia.

Authors:  Sameh Amara; Jorge Domenech; Faouzi Jenhani
Journal:  HIV AIDS (Auckl)       Date:  2010-10-06

Review 6.  Gene Therapy Approaches to Functional Cure and Protection of Hematopoietic Potential in HIV Infection.

Authors:  Tetsuo Tsukamoto
Journal:  Pharmaceutics       Date:  2019-03-11       Impact factor: 6.321

7.  HIV Impacts CD34+ Progenitors Involved in T-Cell Differentiation During Coculture With Mouse Stromal OP9-DL1 Cells.

Authors:  Tetsuo Tsukamoto
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

Review 8.  Hematopoietic Stem/Progenitor Cells and the Pathogenesis of HIV/AIDS.

Authors:  Tetsuo Tsukamoto
Journal:  Front Cell Infect Microbiol       Date:  2020-02-21       Impact factor: 5.293

9.  Methamphetamine Enhances HIV-Induced Aberrant Proliferation of Neural Progenitor Cells via the FOXO3-Mediated Mechanism.

Authors:  Minseon Park; William Baker; Dilraj Cambow; Danielle Gogerty; Ana Rachel Leda; Bridget Herlihy; Darya Pavlenko; Schuyler Van Den Nieuwenhuizen; Michal Toborek
Journal:  Mol Neurobiol       Date:  2021-05-13       Impact factor: 5.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.